RECRUITING Phase 3 ClinicalTrials.gov

A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option

Sponsor: Actelion • ClinicalTrials.gov ID: NCT05179876

Registry updated: 2026-09-25

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Description

The purpose of the study is to enable participants with pulmonary hypertension (PH) currently treated with study intervention(s) in a clinical study (parent studies \[NCT03422328, NCT03904693,NCT04565990, NCT02932410, NCT03492177, and NCT04175600\]), to continue to benefit from the intervention after closure of the parent study in case they have no alternative means of access to the study intervention. This study will allow assessment of the long-term safety of each study intervention.

Interventions

Macitentan (Drug)
Adult participants will receive oral dose of macitentan 10 milligrams (mg) tablet once daily. Children greater than or equal to (\>=) 2 year to less than (\<) 18 years will be given an oral macitentan dose tailored to their body weight, ensuring an equivalent level of systemic exposure as in adults.
Selexipag (Drug)
Adult Participant will receive oral dose of selexipag tablet twice daily at the dose strength corresponding to their maintenance dose at the end of their parent study. Available strengths: 200, 400, 600, 800, 1000, 1200, 1400 and 1600 micrograms (µg). Children with body weight category of \>=50 kg will use the tablets at the required dose strength as described for adults. Children with a body weight \< 50 kg will receive tablets for pediatric use (dose strengths: 100 and 150 mcg), twice daily to enable continuation of individually maximum tolerated dose of selexipag according to their body weight category.
Macitentan/Tadalafil FDC (Drug)
Participants will receive oral FDC of macitentan 10 mg and tadalafil 40 mg once daily during the course of the study as already received in the parent studies.

Eligibility criteria

Inclusion Criteria: * Participant must sign an informed consent form (ICF) (or their legally designated representative must sign) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study * Participant treated with oral macitentan or selexipag or fixed dose combination (FDC) of macitentan 10 milligrams (mg) and tadalafil 40 mg at the end of a sponsor parent study and: a) the indication of the parent study is included in the intervention-specific appendices (ISA) (pulmonary arterial hypertension \[PAH\]; b) participant has completed the parent study; c) no alternative means of access to study intervention (or equivalent approved therapy) have been identified; d) participant may continue to benefit from treatment with the study intervention; e) Participant is at least 18 years old for macitentan/tadalafil FDC, and at least 2 years old for macitentan or selexipag * A female participant of childbearing potential must: a) have a negative urine or serum pregnancy test prior to first intake of study intervention; b) agree to perform monthly urine pregnancy test up to the end of the safety follow-up period; c) If heterosexually active, agree to follow contraceptive methods until 30 days after the last intake of the study intervention. For pediatric female participants: It is the responsibility of the investigator to ensure appropriate counselling, including consultation with a specialist (if needed), to the participant and/or parent(s)/ legally designated representative (LDR)(s) on the acceptable method of contraception Exclusion Criteria: General: * Participants prematurely discontinued from the study intervention in their parent study * Female participant being pregnant, or breastfeeding, or planning to become pregnant while enrolled in this study * Planned or current treatment with another investigational treatment Macitentan-specific: * Known allergies, hypersensitivity, or intolerance to macitentan or its excipients * Hemoglobin less than (\<) 80 grams per liter (g/L) * Serum aspartate (AST) and/or alanine aminotransferases (ALT) greater than (\>) 3\* upper limit of normal (ULN) * Known and documented severe hepatic impairment that is, Child-Pugh Class C. For participants with hepatic impairment, Child-Pugh Class (Child-Pugh score) should be fully assessed and documented in the source documents at screening Selexipag-specific: * Known allergies, hypersensitivity, or intolerance to selexipag or its excipients * Suspected or known pulmonary veno-occlusive disease (PVOD) * Uncontrolled thyroid disease * Severe coronary heart disease or unstable angina, myocardial infarction within the last 6 months, decompensated cardiac failure (if not under close medical supervision), severe arrhythmia, cerebrovascular events (for example, transient ischemic attack, stroke) within the last 3 months, or congenital or acquired valvular defects with clinically relevant myocardial function disorders not related to pulmonary hypertension (PH) * Known and documented severe hepatic impairment that is, Child-Pugh Class C. For participants with hepatic impairment, Child-Pugh Class (Child-Pugh score) should be fully assessed and documented in the source documents at screening * Children only: (a) Current suspicion of intussusception or ileus or gastrointestinal obstruction, per the investigator's judgment; (b) hemoglobin or hematocrit \<75 percent (%) of the lower limit of normal range Macitentan/tadalafil FDC-specific: * Known allergies, hypersensitivity, or intolerance to macitentan or tadalafil or their excipients * Hemoglobin \<80 g/L * Serum aspartate (AST) and/or alanine aminotransferases (ALT) \>3\* ULN range * Known and documented severe hepatic impairment that is, Child-Pugh Class C. For participants with hepatic impairment, Child-Pugh Class should be fully assessed and documented in the source documents at screening * Severe renal impairment (estimated glomerular filtration rate \[eGF\]/creatinine clearance \<30 milliliter per minute \[mL/min\])

Conditions

Hypertension, Pulmonary

Locations

The Republican Scientific-Practical Center ''Cardiology'' — Minsk, Belarus
Minsk Regional Clinical Hospital Of The Red Banner Of Labor — Minsk, Belarus
UZ Leuven — Leuven, Belgium
University Multiprofile Hospital for Active Treatment- UMHAT Sveta Anna AD — Sofia, Bulgaria
Beijing Anzhen Hospital 1 — Beijing, China
Beijing Anzhen Hospital — Beijing, China
The Second Xiangya Hospital of Central South Hospital — Changsha, China
Jiangsu Province Hospital — Nanjing, China
Qingdao Women and Children's Hospital — Qingdao, China
Childrens Hospital of Shanghai — Shanghai, China
The First Affiliated Hospital of Xian Jiaotong University — Xi'an, China
Gottsegen György Országos Kardiológiai Intézet — Budapest, Hungary
Klinika Kardiologii Z Oddzialem Intensywnego Nadzoru Kardiologicznego UM W Bialymstoku — Bialystok, Poland
Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy, Klinika Kardiologii — Bydgoszcz, Poland
SPSK nr 7 SUM w Katowicach Gornoslaskie Centrum Medyczne im Prof Leszka Gieca — Katowice, Poland
Oddzial Kardiologii Wojewodzki Szpital Specjalistyczny im W Bieganskiego — Lodz, Poland
Wojewodzki Szpital Specjalistyczny im Stefana Kardynala Wyszynskiego SPZOZ — Lublin, Poland
SPSK2 PUM Klinika Kardiologii — Szczecin, Poland
Wojewodzki Szpital Specjalist Osrodek Badawczo Rozwojowy — Wroclaw, Poland
Wojewodzki Szpital Specjalistyczny we Wroclawiu — Wroclaw, Poland
Scientific and Research Institution of Cardiovascular Diseases Complex Problems — Kemerovo, Russia
E.Meshalkin National Medical Research Center of the Ministry of Health of the Russian Federation — Novosibirsk, Russia
Federal State Budgetary Institution — Saint Petersburg, Russia
Institute of Cardiology of Tomsk National Research Medical Center of Rus Academy of Sciences — Tomsk, Russia
Regional Clinical Hospital No1 — Tyumen, Russia
Abdullah, IA — Durban, South Africa
Dr Kalla — Lenasia, South Africa
Chungnam National University Hospital — Daejeon, South Korea
Gachon University Gil Medical Center — Incheon, South Korea
Seoul National University Hospital 1 — Seoul, South Korea
Seoul National University Hospital — Seoul, South Korea
Asan Medical Center — Seoul, South Korea
Samsung Medical Center — Seoul, South Korea
The Catholic University of Korea Seoul St Marys Hospital — Seoul, South Korea
Kaohsiung Veterans General Hospital — Kaohsiung City, Taiwan
National Cheng Kung University Hospital — Tainan, Taiwan
National Taiwan University Hospital — Taipei, Taiwan
Taipei Veterans General Hospital — Taipei, Taiwan
Chang-Gung Memorial Hospital, LinKou Branch — Taoyuan, Taiwan
Maharaj Nakorn Chiang Mai hospital Faculty of Medicine — Chiang Mai, Thailand
Municipal Inst. Of Dnipropetrovsk Region. Council — Dnipro, Ukraine
State Institute Of Phthisiology And Pulmonology N.A. F.G. Yanovskiy Of Ams Ukraine — Kyiv, Ukraine
Hanoi Heart Hospital — Hanoi, Vietnam
Hanoi Medical University Hospital — Hanoi, Vietnam
Children's Hospital 1 — Ho Chi Minh City, Vietnam

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record

Accelerate Your Clinical Trial Recruitment